May 26 from 08:00 to 16:45
Room: Drayton Valley
Trainee Day Program

Objective: To provide trainees from all backgrounds (basic/translational research, medicine, industry) with an up-to-date overview of the fundamentals of ovarian cancer, topics under debate and emerging areas in research and clinical care. 

Welcome, Opening Remarks

Lynne-Marie Postovit, Co-Chair CCOCR 2018 Organizing Committee                                              
Elisabeth Baugh, Ovarian Cancer Canada

Pathobiology of ovarian cancer

Basic overview of ovarian cancer pathobiology
Trainees will learn about the unique histopathology of the most common types of ovarian cancer, including characteristic biomarkers.
Speaker: Martin Koebel, MD; University of Calgary

What is the source of high-grade serous carcinoma?
Trainees will be presented with up-to-date data on a fallopian tube vs. ovarian origin of high-grade serous carcinoma, and potential implications on early                                                       detection and clinical management.
Speaker: Ted Brown, PhD; University of Toronto

Endometriosis: A precursor of ovarian cancer?
Trainees will be presented with data supporting the role of endometriosis in endometrioid and clear cell carcinoma.
Speaker: Michael Anglesio, PhD; BC Cancer Agency

Break-out session 1: Origins of ovarian cancer

Coffee Break

Clinical management

Overview of current clinical management 
Description of the “typical” clinical course of women from time of diagnosis, through treatment, to end of life.
Speaker: Helen Steed, MD.; University of Alberta

Emerging role of immune therapy in ovarian cancer treatment
Trainees will be presented with data on different immune therapies that may benefit women with ovarian cancer.
Speaker: Brad Nelson, PhD.; University of Victoria.

Is neoadjuvant chemotherapy beneficial or harmful?
Trainees will be presented with conflicting data on the impact of neoadjuvant chemotherapy in women with ovarian cancer. 
Speaker: Taymaa May, MD. Princess Margaret Cancer Centre.

Break-out session 2: Ovarian cancer treatment.

12:00 -13:30                       
- Living with Cancer: A Perspective                                                   
Moderator: John Robinson, PhD. University of Calgary

Risk and prevention

Inherited predisposition and genetic counselling 
Trainees will learn about the contribution of inherited mutations in BRCA1 and 2, Lynch Syndrome genes and emerging moderate risk genes to hereditary                                                  ovarian cancer, and the important role of genetic counselling.
Speaker: Maria Farag, MSc, CCGC University of Alberta Hospital

Surgical and non-surgical options for ovarian cancer risk reduction
Trainees will learn about the surgical options for risk reduction in women at high risk and the general population, in addition to non-surgical alternatives such                                                as oral contraceptives and aspirin.
Speaker:  Alicia Tone, PhD. Princess Margaret Cancer Centre.

Break-out session 3: genetic predisposition

Health break

The scientific tool box

Experimental models of ovarian cancer 
Trainees will learn about the advantages and drawbacks of available model systems, such as cell culture, patient-derived xenografts and mouse models.
Speaker: Barbara Vanderhyden, PhD; University of Ottawa

“Omics” of ovarian cancer
Trainees will learn about next-generation sequencing techologies and new biologic samples of interest, such as circulating tumour DNA.  
Speaker: Jim Petrik, PhD. University of Guelph

Closing and Evaluations

Go back